Markt oder Branche auswählen:
Chart-Typ:
Zeitraum:
| Icelandair Group hf.: Financial results Q1 2024 | Revenue increase of 11%, total income USD 259.0 millionRecord passenger revenue USD 199.0 million up by 17% from last year5% decrease in unit costFleet renewal and focus on operational efficiencies... ► Artikel lesen |
| Icelandair Group hf.: Considerable increase on the via market, improved load factor and on-time performance | In March 2024, Icelandair transported 298 thousand passengers, which represents a 25% increase in passenger traffic as measured by Revenue Passenger Kilometers (RPK) on a capacity increase of 22%... ► Artikel lesen |
| Icelandair Group hf.: Results of the Annual General Meeting | Icelandair Group's Annual General Meeting was held today at 4pm and the results were as follows: Annual Accounts and dividends(Item 2) The Board submitted the audited Consolidated Financial Statements... ► Artikel lesen |
| Festi hf.: Financial results for Q1 2024 | Key findings Sale of goods amounted to ISK 32,223 million, compared to ISK 29,484 million in the previous year, an increase of 9.3% between years.Gross profit from sales of goods and services amounted... ► Artikel lesen |
| Festi hf.: Festi hf: Festi acquisition of all shares in Lyfja hf. - Conciliation talks begin with the Icelandic Competition Authority. | The Icelandic Competition Authority has agreed to Festi's request to start conciliation talks on possible remedies associated with Festi's acquisition of all shares in Lyfja hf. The conciliation talks... ► Artikel lesen |
| Festi hf.: Festi hf: Festi acquisition of all shares in Lyfja hf. - Request for conciliation talks with the Icelandic Competition Authority. | Reference is made to Festi's announcement, published on the 18th of March 2024, regarding the preliminary conclusions in the Icelandic Competition Authority's investigation into the competitive effects... ► Artikel lesen |
| Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi (golimumab) | The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid... ► Artikel lesen |
| Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira (adalimumab) | Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar... ► Artikel lesen |
| Teva Pharmaceutical Industries Limited: Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) | SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
